Skip to content
Assyro AI
Purple Book reference family ยท 351(a) biologic

ustekinumab (Stelara)

ustekinumab is an FDA-licensed reference biologic from Janssen Biotech, Inc., with 8 approved follow-on biologics.

351(a) biologicBLA 125261 Janssen Biotech, Inc.
Biosimilars
0
Interchangeables
8
Listed patents
12
Reference approved
2009

Reference product

Originator biologic
Ask AI
351(a)BLA 125261

Stelara ustekinumab

Janssen Biotech, Inc.

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
12 listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for ustekinumab from the RCSB Protein Data Bank (PDB 3HMW).

3D molecular structure of ustekinumab (PDB entry 3HMW)

Interactive biological assembly from PDB entry 3HMW. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
Ask AI
  1. Reference approval

    Approval date of the reference ustekinumab product.

    17 yr 5 mo ago

  2. Patent 6,902,734 expires

    Published Purple Book patent expiration.

    3 yr 2 mo ago

  3. Patent 6,902,734 expires

    Published Purple Book patent expiration.

    3 yr 2 mo ago

  4. Patent 8,852,889 expires

    Published Purple Book patent expiration.

    in 5 yr 8 mo

  5. Patent 8,852,889 expires

    Published Purple Book patent expiration.

    in 5 yr 8 mo

  6. Patent 9,475,858 expires

    Published Purple Book patent expiration.

    in 5 yr 8 mo

  7. Patent 9,475,858 expires

    Published Purple Book patent expiration.

    in 5 yr 8 mo

  8. Patent 9,217,168 expires

    Published Purple Book patent expiration.

    in 6 yr 5 mo

  9. Patent 9,217,168 expires

    Published Purple Book patent expiration.

    in 6 yr 5 mo

  10. Patent 9,663,810 expires

    Published Purple Book patent expiration.

    in 6 yr 5 mo

  11. Patent 9,663,810 expires

    Published Purple Book patent expiration.

    in 6 yr 5 mo

  12. Patent 10,961,307 expires

    Published Purple Book patent expiration.

    in 13 yr

  13. Patent 10,961,307 expires

    Published Purple Book patent expiration.

    in 13 yr

Biosimilars & interchangeables for ustekinumab

Follow-on biologics
Ask AI
Biosimilars and interchangeable biosimilars referencing ustekinumab.
ProductProper nameApplicantTypeBLAApproved
Wezlanaustekinumab-auubAmgen Inc.Interchangeable761331
Selarsdiustekinumab-aeknAlvotech USA Inc.Interchangeable761343
Pyzchivaustekinumab-ttweSamsung Bioepis Co., Ltd.Interchangeable761425
Imuldosaustekinumab-srlfAccord BioPharma Inc.Interchangeable761364
Yesintekustekinumab-kfceBiocon Biologics Inc.Interchangeable761406
Steqeymaustekinumab-stbaCELLTRION, Inc.Interchangeable761338
Otulfiustekinumab-aauzFresenius Kabi USA, LLCInterchangeable761379
Starjemzaustekinumab-hmnyBio-Thera Solutions, Ltd.Interchangeable761419

Published patents

Purple Book patent list
Ask AI
Published Purple Book patents for ustekinumab.
PatentExpiresIn
6,902,7343 yr 2 mo ago
6,902,7343 yr 2 mo ago
8,852,889in 5 yr 8 mo
8,852,889in 5 yr 8 mo
9,475,858in 5 yr 8 mo
9,475,858in 5 yr 8 mo
9,217,168in 6 yr 5 mo
9,217,168in 6 yr 5 mo
9,663,810in 6 yr 5 mo
9,663,810in 6 yr 5 mo
10,961,307in 13 yr
10,961,307in 13 yr

ustekinumab: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for ustekinumab.

Related FDA reference tools

Assyro Intelligence

Ask anything about ustekinumab

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo